CARB-X
VC Fund
Boston, United States
CARB-X is a VC fund in Boston focused on Biotechnology and Health Care. Accelerate a diverse portfolio of at least 20 high-quality antibacterial products towards clinical development leveraging $250 million in BARDA funds with matching funds from the Wellcome Trust and the AMR Centre.
- Total investments:
- 149
- Last investment:
- Lead investor:
- 94%
- Fund size:
- $370M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries CARB-X invests in
Stages CARB-X invests in
Countries CARB-X invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 73 (49%)
- Health Care 43 (29%)
- Medical 29 (19%)
- Pharmaceutical 27 (18%)
- Therapeutics 20 (13%)
Stage
- Grant 86 (58%)
- Seed 1 (1%)
Country
- United States 48 (32%)
- United Kingdom 11 (7%)
- Switzerland 8 (5%)
- Australia 4 (3%)
- India 3 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Diane MacDonald
Chief Operating Officer
|
Chief Operating Officer | Total investments: 0 | Find email | |
Kevin Outterson
Executive Director
|
Executive Director | Total investments: 34 | Find email | |
Richard Alm
Chief Scientific Officer
|
Chief Scientific Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| AdJane develops vaccine adjuvants to enhance immune response and support safer, more effective vaccines. | $2.6M / Grant / Apr 28, 2026 | ||
| Macro Biologics creates synthetic biological polymers for therapeutic and biotechnology applications. | $5M / Grant / Dec 16, 2025 | ||
| ProtonDx is a diagnostic platform that provides molecular testing services. They combine speed, sensitivity, specificity, and convenience to differentiate and detect multiple pathogens from the sample. They respond to customer inquiries by contact form and email. | $1M / Seed / Dec 04, 2025 | ||
| Seres Therapeutics is a microbiome therapeutics company focused on discovering and developing Ecobiotic therapeutic products. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbioticmicrobiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401. | $3.6M / Grant / Oct 29, 2025 | ||
| Baxiva is an emerging biotechnology startup focused on the development of next-generation glycoconjugate vaccines designed to prevent and combat bacterial infections. By leveraging advanced glycoengineering technologies and innovative vaccine platforms, Baxiva aims to create more effective and longer-lasting immunizations that address both existingand emerging bacterial threats. | $3M / Grant / Aug 21, 2025 | ||
| Kinvard Bio provides to advance these antibiotics to the clinical stage under the leadership | $2.7M / Grant / Jul 29, 2025 | ||
| LimmaTech Biologics AG is a clinical-stage biopharmaceutical company. | $6.5M / Grant / Feb 17, 2025 | ||
| Visby Medical is a diagnostics company that develops PCR-based diagnostic tests for the detection of infectious diseases. The company develops a device platform that aims to redefine the way an illness is tested and treated. They believe that by taking a human-centric, technology-first approach to device development and they can create tools thatare both highly accurate and delightful to use. | $3.9M / Grant / Jan 15, 2025 | ||
| Melio provides a quick and comprehensive blood test that detects all prevalent infections. Their technology allows for prompt and targeted therapy while also combating antibiotic resistance. Melio is headquartered in Santa Clara, California. | $3.5M / Grant / Jan 14, 2025 | ||
| Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the integrated research, development and commercial operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd., the company focuses on providing innovative pharmaceutical products in the therapeutic areas ofbacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and nonresponse to current treatment options. | $7.3M / Grant / Dec 23, 2024 | ||
| See all 149 investments → | |||
Co-Investors
AAF Management Ltd.
2 deals together
AAF Management Ltd.
2 deals together
Bill & Melinda Gates Foundation
1 deal together
Biomedical Advanced Research and Development Authority (BARDA)
1 deal together
Department of Health and Social Care (DHSC)
1 deal together
German Federal Ministry of Research, Technology and Space
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does CARB-X invest in?
CARB-X invests primarily in Biotechnology, Health Care and Medical startups, most often at Grant and Seed stage. Most of the 149 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact CARB-X?
Public channels for CARB-X include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CARB-X?
The team at CARB-X includes Diane MacDonald (Chief Operating Officer), Kevin Outterson (Executive Director) and Richard Alm (Chief Scientific Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
